Még nem toboroz
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
2025-525022-35-00· 3. fázis· Hunan Mabgeek Biotech Co. Ltd.· Forrás
Még nem toboroz
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
NCT07873801· 3. fázis· Almirall, S.A.· Forrás
Még nem toboroz
Multicenter, open label, phase II clinical trial evaluating the combination of elranatamab with mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma
2026-526352-31-00· 2. fázis· Fundacion PETHEMA· Forrás
Toboroz
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161· 3. fázis· Takeda· Forrás
Még nem toboroz
Rollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Benefited from Continued Treatment.
2026-526419-13-00· 3. fázis· AstraZeneca AB· Forrás
Toboroz
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
NCT07665437· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Safety and efficacy of treatment combination with ponatinib and asciminib in chronic myeloid leukemia patients resistant to ponatinib and/or asciminib
2025-521126-15-00· 2. fázis· Grupo Espanol De Leucemia Mieloide Cronica (GELMC)· Forrás
Toboroz
Phase 1/2 multicenter, two-arms, open-label, dose-escalation study of IDP-121 in combination with chemotherapy in patients with relapsed small cell lung cancer (SCLC) (MYCrocytic)
2025-521902-17-00· 1/2. fázis· Idp Discovery Pharma S.L.· Forrás
Toboroz
A study to evaluate the safety and efficacy of oral decitabine plus ivosidenib in newly diagnosed adult patients with acute myeloid leukemia older than 60 years and/or inelegible for standard induction chemotherapy
2025-523238-17-00· 2. fázis· Fundacion PETHEMA· Forrás
Toboroz
A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial
2025-524078-40-00· 3. fázis· Novartis Pharma AG· Forrás
Még nem toboroz
Clinical trial to assess the efficacy and safety of a vaccine for dust mite and Blomia tropicalis allergy.
2025-522773-12-00· 3. fázis· Inmunotek S.L.· Forrás
Toboroz
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s ineligible for standard induction chemotherapy
2025-522979-29-00· 3. fázis· Fundacion PETHEMA· Forrás
Fut, nem toboroz
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
2025-522440-41-00· 2. fázis· Bluefin Biomedicine Inc.· Forrás
Toboroz
Phase 2 Study of iadademstat for the treatment of patients with essential thrombocythemia resistant/intolerant to hydroxyurea.
2025-523864-19-00· 2. fázis· Oryzon Genomics S.A.· Forrás
Toboroz
Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER)
NCT07611747· 4. fázis· Instituto de Investigación Marqués de Valdecilla· Forrás
Toboroz
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
2025-521546-23-00· 3. fázis· Novartis Pharma AG· Forrás
Toboroz
Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia
NCT07394153· 2. fázis· Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas· Forrás
Toboroz
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
NCT07431177· 2. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Evaluation of efficacy and safety of early in hospital initiation of inclisiran treatment in patients with acute coronary syndromes
2025-521670-34-00· 3. fázis· Novartis Pharma AG· Forrás
Toboroz
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
NCT07325292· 3. fázis· Sanofi· Forrás
Toboroz
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
NCT07095452· 2/3. fázis· AbbVie· Forrás
Toboroz
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
NCT07107529· 2. fázis· European Myeloma Network B.V.· Forrás
Toboroz
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
NCT07211958· 3. fázis· Syndax Pharmaceuticals· Forrás
Fut, nem toboroz
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
NCT07074886· 2. fázis· Hoffmann-La Roche· Forrás
Toboroz
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
NCT07170917· 2. fázis· Sanofi· Forrás
Fut, nem toboroz
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
NCT07108283· 2. fázis· Takeda· Forrás
Toboroz
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
2024-516654-22-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis
2024-519795-11-00· 2. fázis· Apogee Therapeutics Inc.· Forrás
Toboroz
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
NCT06745908· 3. fázis· ImmunityBio, Inc.· Forrás
Toboroz
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187· 3. fázis· BeOne Medicines· Forrás
Még nem toboroz
Exploring the Anti-ageing Effects of Metformin in COPD
NCT06999343· 3. fázis· Fundación Instituto de Investigación Sanitaria de Navarra· Forrás
Toboroz
PALACE: Cemiplimab Trial According to ctDNA Levels
NCT06917573· 2. fázis· Fundación GECP· Forrás
Toboroz
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)
NCT07153445· 2. fázis· Fundación GECP· Forrás
Toboroz
A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
NCT06979375· 2. fázis· Novo Nordisk A/S· Forrás
Toboroz
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
NCT06979362· 2. fázis· Novo Nordisk A/S· Forrás
Toboroz
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
NCT06409936· 2. fázis· Gruppo Italiano Malattie EMatologiche dell'Adulto· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT07037901· 2. fázis· Inmagene LLC· Forrás
Fut, nem toboroz
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
NCT06958211· 3. fázis· Incyte Corporation· Forrás
Toboroz
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
2023-510294-34-00· 3. fázis· University Of Cologne· Forrás
Még nem toboroz
REstoration with calcifediol of VItamin D deficiency in pulmonary Arterial Hypertension patients (REVIDAH study)
2025-521694-14-00· 4. fázis· Consorci Mar Parc De Salut De Barcelona· Forrás
Toboroz
Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
NCT05815927· 3. fázis· European Organisation for Research and Treatment of Cancer - EORTC· Forrás
Toboroz
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
NCT06947993· 2. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Study to evaluate the safety and efficacy of a treatment consisting of immunotherapy by subcutaneous injection of a combination of Der p 1/Der p 2/Der p 23 allergens at different doses in patients with allergic rhinitis or rhinoconjunctivitis with or without allergic asthma.
2024-518519-20-01· 2. fázis· Diater Laboratorio De Diagnostico Y Aplicaciones Terapeuticas S.A.· Forrás
Fut, nem toboroz
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06840392· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
NCT06517875· 2. fázis· GlaxoSmithKline· Forrás
Showing 50 of 91.